Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.1 USD | -1.68% | -3.07% | -25.45% |
15/05 | Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M | MT |
30/04 | Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.45% | 3.72Cr | |
+33.37% | 4.95TCr | |
+1.55% | 4.26TCr | |
+49.11% | 4.25TCr | |
-4.22% | 2.91TCr | |
+11.57% | 2.66TCr | |
-21.00% | 1.86TCr | |
+7.36% | 1.32TCr | |
+28.30% | 1.25TCr | |
+23.80% | 1.21TCr |
- Stock Market
- Equities
- MRKR Stock
- News Marker Therapeutics, Inc.
- Marker Therapeutics Says MT-401 Non-clinical Data Show Anti-Tumor Activity Against Acute Myeloid Leukemia